Evidence map›Paper›PMID 42665571›Full record

ArticleBritish journal of haematology2026

Functional assessment of inherited myeloid neoplasm-associated SAMD9L germline variants via Monoallelic CRISPR modelling.

Elena Vuelta, Alessandro Liquori, Matias Morín, Lucia Soletto, Miguel Ángel Marugal, Marta Santiago-Balsera, Miguel Gallardo, Miguel Ángel Moreno-Pelayo, José Cervera, Alejandra Sanjuan-Pla

Abstract read
PubMed Publisher
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Elena VueltaHematology Research Group, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
Alessandro LiquoriHematology Research Group, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.ORCID https://orcid.org/0000-0002-4842-5986
Matias MorínDepartment of Genetics, Hospital Universitario Ramón y Cajal (IRYCIS) and Biomedical Network Research Centre on Rare Diseases (CIBERER), Madrid, Spain.ORCID https://orcid.org/0000-0002-7985-592X
Lucia SolettoDepartment of Genetics, Hospital Universitario Ramón y Cajal (IRYCIS) and Biomedical Network Research Centre on Rare Diseases (CIBERER), Madrid, Spain.ORCID https://orcid.org/0000-0002-5768-5317
Miguel Ángel MarugalDepartment of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.ORCID https://orcid.org/0009-0009-2869-5522
Marta Santiago-BalseraHematology Research Group, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
Miguel GallardoDepartment of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.ORCID https://orcid.org/0000-0002-3699-9130
Miguel Ángel Moreno-PelayoDepartment of Genetics, Hospital Universitario Ramón y Cajal (IRYCIS) and Biomedical Network Research Centre on Rare Diseases (CIBERER), Madrid, Spain.ORCID https://orcid.org/0000-0003-3839-5098
José CerveraHematology Research Group, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
Alejandra Sanjuan-PlaHematology Research Group, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.ORCID https://orcid.org/0000-0002-0170-5542

Funding

Instituto de Salud Carlos III PI22/01633Instituto de Salud Carlos III PI25/01629Ministerio de Educación y Ciencias PID2022-136660OB-I00
6 · The paper itself

Abstract

While the majority of myeloid neoplasms are sporadic, the increasing application of germline genetic testing has led the World Health Organization to designate 'Myeloid malignancies with germline predisposition' as a distinct clinical entity, carrying major implications for clinical care and research. Germline variants in the Sterile alpha motif domain-containing 9-like (SAMD9L) gene are specifically associated with an increased risk for these malignancies. In this study, we functionally modelled two novel SAMD9L variants-p.N697Y and p.K1294*-alongside two previously reported variants (p.T233N and p.H880Q). We generated heterozygous knock-in cellular models in the Human leukemia (HL-60 myeloid cell line) for each variant using homology-directed repair-based Clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9 (CRISPR/Cas9) gene editing. Functional assays, focused on proliferation and protein translation, confirmed that the p.T233N, p.N697Y and p.K1294* variants all caused a decreased rate of protein translation. These results provide functional evidence to fine-tune the classification of these SAMD9L variants and significantly advance our understanding of the molecular mechanisms by which SAMD9L variants drive inherited myeloid neoplasms.

Indexed as

CRISPR-Cas SystemsGerm-Line MutationTumor Suppressor ProteinsAllelesGene EditingGenetic Predisposition to DiseaseHL-60 CellsHumansIntracellular Signaling Peptides and ProteinsIntracellular Signaling Peptides and ProteinsSAMD9L protein, humanTumor Suppressor ProteinsCRISPR/Cas9 gene editinginherited myeloid neoplasmsSAMD9L

Identifiers

PMID42665571

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.